Cadrenal Therapeutics raises $5.1M via ATM facility, selling 391,243 shares at $13.15

Cadrenal Therapeutics, Inc.

Gross proceeds of $5.1M from sale of 391,243 shares at weighted avg price of $13.15/share.
Post-sale shares outstanding 1,496,771; cash balance approximately $7.4M as of Oct 23, 2024.
Proceeds to fund tecarfarin development and preparation for pivotal Phase 3 trial.
H.C. Wainwright acted as exclusive sales agent; shelf registration effective March 20, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.